170 related articles for article (PubMed ID: 32871937)
1. Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report.
Ishiguro K; Sasaki Y; Takagi Y; Niinuma T; Suzuki H; Tokino T; Hayashi T; Takahashi T; Igarashi T; Matsuno Y
Medicine (Baltimore); 2020 Aug; 99(35):e21938. PubMed ID: 32871937
[TBL] [Abstract][Full Text] [Related]
2. Splenic marginal zone lymphoma: from genetics to management.
Arcaini L; Rossi D; Paulli M
Blood; 2016 Apr; 127(17):2072-81. PubMed ID: 26989207
[TBL] [Abstract][Full Text] [Related]
3. Risk-tailored treatment of splenic marginal zone lymphoma.
Castelli R; Balzarotti M; Salvi E; Simona Rossi R; Lambertenghi Deliliers G; Bergamaschini L; Gidaro A
Anticancer Drugs; 2022 Jan; 33(1):e36-e42. PubMed ID: 34407041
[TBL] [Abstract][Full Text] [Related]
4. Idelalisib and Rituximab in 17p Deletion-Positive Splenic Marginal Zone Lymphoma.
Philip AZ
J Natl Compr Canc Netw; 2018 Mar; 16(3):230-233. PubMed ID: 29523661
[TBL] [Abstract][Full Text] [Related]
5. [Splenic marginal zone lymphoma complicated by cold agglutinin disease].
Ochi K; Yokoyama K; Ohno N; Ota Y; Tojo A
Rinsho Ketsueki; 2017; 58(2):132-137. PubMed ID: 28321090
[TBL] [Abstract][Full Text] [Related]
6. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
Bennett M; Schechter GP
Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
[TBL] [Abstract][Full Text] [Related]
7. Splenic marginal zone lymphoma with monoclonal IgG: A case report.
Zhang X; Ren S; Zhang N; Wang X; Qiu L; Sun H; Yi H; Fan F
Medicine (Baltimore); 2024 Feb; 103(6):e37158. PubMed ID: 38335376
[TBL] [Abstract][Full Text] [Related]
8. Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center.
de Pádua Covas Lage LA; Dos Santos FFC; Levy D; Moreira FR; Couto SCF; Culler HF; de Oliveira Costa R; Rocha V; Pereira J
BMC Cancer; 2020 Aug; 20(1):717. PubMed ID: 32746790
[TBL] [Abstract][Full Text] [Related]
9. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJG; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Hematology; 2017 Aug; 22(7):405-411. PubMed ID: 28105889
[TBL] [Abstract][Full Text] [Related]
10. [Progress on Treatment of Splenic Marginal Zone Lymphoma-Review].
Wu L; Tian C; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):600-603. PubMed ID: 28446319
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
[TBL] [Abstract][Full Text] [Related]
12. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma.
Olszewski AJ; Ali S
Ann Hematol; 2014 Mar; 93(3):449-58. PubMed ID: 24057925
[TBL] [Abstract][Full Text] [Related]
13. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.
Kalpadakis C; Pangalis GA; Angelopoulou MK; Sachanas S; Kontopidou FN; Yiakoumis X; Kokoris SI; Dimitriadou EM; Dimopoulou MN; Moschogiannis M; Korkolopoulou P; Kyrtsonis MC; Siakantaris MP; Papadaki T; Tsaftaridis P; Plata E; Papadaki HE; Vassilakopoulos TP
Oncologist; 2013; 18(2):190-7. PubMed ID: 23345547
[TBL] [Abstract][Full Text] [Related]
14. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
Cervetti G; Galimberti S; Pelosini M; Ghio F; Cecconi N; Petrini M
Ann Oncol; 2013 Sep; 24(9):2434-8. PubMed ID: 23712547
[TBL] [Abstract][Full Text] [Related]
15. Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?
Kalpadakis C; Pangalis GA; Vassilakopoulos TP; Sachanas S; Angelopoulou MK
Leuk Lymphoma; 2014 Jul; 55(7):1463-70. PubMed ID: 24050506
[TBL] [Abstract][Full Text] [Related]
16. [Successful treatment with rituximab in a patient with splenic marginal zone B-cell lymphoma accompanied by cold agglutinin disease].
Yasuyama M; Kawauchi K; Otsuka K; Tamura H; Fujibayashi M
Nihon Ronen Igakkai Zasshi; 2014; 51(6):569-75. PubMed ID: 25749330
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in a patient with splenic marginal zone lymphoma and acquired angioedema.
Motosue MS; Howard MT; Butterfield JH
Ann Allergy Asthma Immunol; 2016 May; 116(5):472-3. PubMed ID: 27017557
[No Abstract] [Full Text] [Related]
18. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
Tsimberidou AM; Catovsky D; Schlette E; O'Brien S; Wierda WG; Kantarjian H; Garcia-Manero G; Wen S; Do KA; Lerner S; Keating MJ
Cancer; 2006 Jul; 107(1):125-35. PubMed ID: 16700034
[TBL] [Abstract][Full Text] [Related]
19. Splenic Marginal Zone Lymphoma with Acquired von Willebrand Syndrome Diagnosed via Splenic Bleeding.
Komeno Y; Shibuya N; Uryu H; Yamada H; Toda T; Shibasaki M; Kunishima S; Iihara K; Ryu T
Intern Med; 2017; 56(5):557-562. PubMed ID: 28250305
[TBL] [Abstract][Full Text] [Related]
20. Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL).
Cervetti G; Galimberti S; Sordi E; Buda G; Orciuolo E; Cecconi N; Petrini M
Ann Oncol; 2010 Apr; 21(4):851-854. PubMed ID: 19825880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]